Micrornas: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer

Theranostics

Volumn 5, Issue 10, 2015, Pages 1122-1143

  Bertoli, Gloria ^a   Cava, Claudia ^a   Castiglioni, Isabella ^a  

^a INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

Author keywords

Breast cancer; Circulating biomarker; Diagnosis; Microrna mirna; Prediction and therapy; Prognosis; Theranostic

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DAUNORUBICIN; MICRORNA; MICRORNA 10B; MICRORNA 145; MICRORNA 148A; MICRORNA 150; MICRORNA 155; MICRORNA 17 5P; MICRORNA 187; MICRORNA 195; MICRORNA 200C; MICRORNA 203; MICRORNA 206; MICRORNA 21; MICRORNA 210; MICRORNA 30C; MICRORNA 335; MICRORNA 339 5P; MICRORNA 34A; MICRORNA 9; MICRORNA 92A; MICRORNA LET 7; MRX 34; UNCLASSIFIED DRUG; TUMOR MARKER;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER MODEL; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL PROLIFERATION; DIFFERENTIAL DIAGNOSIS; DOWN REGULATION; EARLY DIAGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; IMMUNOPRECIPITATION; INTERACTIONS WITH RNA; LUCIFERASE ASSAY; METASTASIS; MOLECULAR PATHOLOGY; NONHUMAN; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); RISC IMMUNOPRECIPITATION; RNA SYNTHESIS; TUMOR INVASION; UPREGULATION; ANIMAL; BREAST NEOPLASMS; FEMALE; GENE THERAPY; GENETICS; METABOLISM; PROGNOSIS;

ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; MICRORNAS; PROGNOSIS;

EID: 84942523631     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.11543     Document Type: Article

References (247)

1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854.
2. Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 2013; 14: 475-488.
3. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014; 42: D68-73.
4. Griffiths-Jones S, Grocock RJ, van Dongen S, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006; 34: D140-144.
5. Herranz H, Cohen SM. MicroRNAs and gene regulatory networks: managing the impact of noise in biological systems. Genes Dev 2010; 24: 1339-1344.
6. Femminella GD, Ferrara N, Rengo G. The emerging role of microRNAs in Alzheimer's disease. Front Physiol 2015; 6: 40.
7. Kondkar AA, Abu-Amero KK. Utility of Circulating MicroRNAs as Clinical Biomarkers for Cardiovascular Diseases. Biomed Res Int 2015; 2015: 821823.
8. McClelland AD, Kantharidis P. microRNA in the development of diabetic complications. Clin Sci (Lond) 2014; 126: 95-110.
9. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev 2011; 91: 827-887.
10. Palmero EI, de Campos SG, Campos M, et al. Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet Mol Biol 2011; 34: 363-370.
11. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-386.
12. Rakha EA, El-Sayed ME, Menon S, et al. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat 2008; 111: 121-127.
13. Viale G. The current state of breast cancer classification. Ann Oncol 2012; 23 Suppl 10: x207-210.
14. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628-3636.
15. Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol 2010; 23 Suppl 2: S60-64.
16. Jiang D, Zhao N. A clinical prognostic prediction of lymph node-negative breast cancer by gene expression profiles. J Cancer Res Clin Oncol 2006; 132: 579-587.
17. Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 2013; 329: 125-136.
18. Qu H, Xu W, Huang Y, Yang S. Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev 2011; 12: 1117-1125.
19. Ashby J, Flack K, Jimenez LA, et al. Distribution profiling of circulating microRNAs in serum. Anal Chem 2014; 86: 9343-9349.
20. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011; 108: 5003-5008.
21. Cava C, Bertoli G, Ripamonti M, et al. Integration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition. PLoS One 2014; 9: e97681.
22. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014; 15: 509-524.
23. Vidaurre S, Fitzpatrick C, Burzio VA, et al. Down-regulation of the antisense mitochondrial non-coding RNAs (ncRNAs) is a unique vulnerability of cancer cells and a potential target for cancer therapy. J Biol Chem 2014; 289: 27182-27198.
24. Czech B, Hannon GJ. Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet 2011; 12: 19-31.
25. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425: 415-419.
26. Denli AM, Tops BB, Plasterk RH, et al. Processing of primary microRNAs by the Microprocessor complex. Nature 2004; 432: 231-235.
27. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003; 17: 3011-3016.
28. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004; 10: 185-191.
29. Lund E, Guttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science 2004; 303: 95-98.
30. Diederichs S, Haber DA. Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell 2007; 131: 1097-1108.
31. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
32. Okamura K, Liu N, Lai EC. Distinct mechanisms for microRNA strand selection by Drosophila Argonautes. Mol Cell 2009; 36: 431-444.
33. Ghildiyal M, Xu J, Seitz H, et al. Sorting of Drosophila small silencing RNAs partitions microRNA* strands into the RNA interference pathway. RNA 2010; 16: 43-56.
34. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008; 30: 460-471.
35. Qin W, Shi Y, Zhao B, et al. miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One 2010; 5: e9429.
36. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci U S A 2007; 104: 9667-9672.
37. Eiring AM, Harb JG, Neviani P, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010; 140: 652-665.
38. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1931-1934.
39. Ekimler S, Sahin K. Computational Methods for MicroRNA Target Prediction. Genes (Basel) 2014; 5: 671-683.
40. Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell 2003; 115: 787-798.
41. Hafner M, Landthaler M, Burger L, et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 2010; 141: 129-141.
42. Broderick JA, Salomon WE, Ryder SP, et al. Argonaute protein identity and pairing geometry determine cooperativity in mammalian RNA silencing. RNA 2011; 17: 1858-1869.
43. Bentwich I, Avniel A, Karov Y, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005; 37: 766-770.
44. Yue D, Liu H, Huang Y. Survey of Computational Algorithms for MicroRNA Target Prediction. Curr Genomics 2009; 10: 478-492.
45. Hofacker IL. How microRNAs choose their targets. Nat Genet 2007; 39: 1191-1192.
46. Kertesz M, Iovino N, Unnerstall U, et al. The role of site accessibility in microRNA target recognition. Nat Genet 2007; 39: 1278-1284.
47. Lindow M, Gorodkin J. Principles and limitations of computational microRNA gene and target finding. DNA Cell Biol 2007; 26: 339-351.
48. Allmer J, Yousef M. Computational methods for ab initio detection of microRNAs. Front Genet 2012; 3: 209.
49. Wang C, Ding C, Meraz RF, Holbrook SR. PSoL: a positive sample only learning algorithm for finding non-coding RNA genes. Bioinformatics 2006; 22: 2590-2596.
50. Yousef M, Jung S, Showe LC, Showe MK. Learning from positive examples when the negative class is undetermined--microRNA gene identification. Algorithms Mol Biol 2008; 3: 2.
51. Kadri S, Hinman V, Benos PV. HHMMiR: efficient de novo prediction of microRNAs using hierarchical hidden Markov models. BMC Bioinformatics 2009; 10 Suppl 1: S35.
52. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500.
53. Huang TH, Fan B, Rothschild MF, et al. MiRFinder: an improved approach and software implementation for genome-wide fast microRNA precursor scans. BMC Bioinformatics 2007; 8: 341.
54. Hertel J, Stadler PF. Hairpins in a Haystack: recognizing microRNA precursors in comparative genomics data. Bioinformatics 2006; 22: e197-202.
55. Nam JW, Shin KR, Han J, et al. Human microRNA prediction through a probabilistic co-learning model of sequence and structure. Nucleic Acids Res 2005; 33: 3570-3581.
56. Terai G, Komori T, Asai K, Kin T. miRRim: a novel system to find conserved miRNAs with high sensitivity and specificity. RNA 2007; 13: 2081-2090.
57. Yousef M, Nebozhyn M, Shatkay H, et al. Combining multi-species genomic data for microRNA identification using a Naive Bayes classifier. Bioinformatics 2006; 22: 1325-1334.
58. Oulas A, Boutla A, Gkirtzou K, et al. Prediction of novel microRNA genes in cancer-associated genomic regions--a combined computational and experimental approach. Nucleic Acids Res 2009; 37: 3276-3287.
59. Maragkakis M, Alexiou P, Papadopoulos GL, et al. Accurate microRNA target prediction correlates with protein repression levels. BMC Bioinformatics 2009; 10: 295.
60. Enright AJ, John B, Gaul U, et al. MicroRNA targets in Drosophila. Genome Biol 2003; 5: R1.
61. Kuhn DE, Martin MM, Feldman DS, et al. Experimental validation of miRNA targets. Methods 2008; 44: 47-54.
62. Thomson DW, Bracken CP, Goodall GJ. Experimental strategies for microRNA target identification. Nucleic Acids Res 2011; 39: 6845-6853.
63. Muniategui A, Pey J, Planes FJ, Rubio A. Joint analysis of miRNA and mRNA expression data. Brief Bioinform 2013; 14: 263-278.
64. Karginov FV, Conaco C, Xuan Z, et al. A biochemical approach to identifying microRNA targets. Proc Natl Acad Sci U S A 2007; 104: 19291-19296.
65. Cambronne XA, Shen R, Auer PL, Goodman RH. Capturing microRNA targets using an RNA-induced silencing complex (RISC)-trap approach. Proc Natl Acad Sci U S A 2012; 109: 20473-20478.
66. Andorfer CA, Necela BM, Thompson EA, Perez EA. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med 2011; 17: 313-319.
67. Shi M, Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev 2009; 35: 328-334.
68. Sotiropoulou G, Pampalakis G, Lianidou E, Mourelatos Z. Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 2009; 15: 1443-1461.
69. Weber B, Stresemann C, Brueckner B, Lyko F. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 2007; 6: 1001-1005.
70. Lehmann U. Aberrant DNA methylation of microRNA genes in human breast cancer - a critical appraisal. Cell Tissue Res 2014; 356: 657-664.
71. Castilla MA, Diaz-Martin J, Sarrio D, et al. MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One 2012; 7: e47709.
72. Wee EJ, Peters K, Nair SS, et al. Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer. Oncogene 2012; 31: 4182-4195.
73. Aure MR, Leivonen SK, Fleischer T, et al. Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. Genome Biol 2013; 14: R126.
74. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9: 435-443.
75. Scott GK, Mattie MD, Berger CE, et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66: 1277-1281.
76. Yamamoto H, Adachi Y, Taniguchi H, et al. Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. World J Gastroenterol 2012; 18: 2745-2755.
77. Lin X, Wu M, Liu P, et al. Up-regulation and worse prognostic marker of cytoplasmic TARBP2 expression in obstinate breast cancer. Med Oncol 2014; 31: 868.
78. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004; 101: 2999-3004.
79. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000; 403: 901-906.
80. Khoshnaw SM, Rakha EA, Abdel-Fatah T, et al. The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients. Breast Cancer Res Treat 2013; 137: 139-153.
81. Khoshnaw SM, Rakha EA, Abdel-Fatah TM, et al. Loss of Dicer expression is associated with breast cancer progression and recurrence. Breast Cancer Res Treat 2012; 135: 403-413.
82. Yan M, Huang HY, Wang T, et al. Dysregulated expression of dicer and drosha in breast cancer. Pathol Oncol Res 2012; 18: 343-348.
83. Dedes KJ, Natrajan R, Lambros MB, et al. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer 2011; 47: 138-150.
84. Han Y, Liu Y, Gui Y, Cai Z. Inducing cell proliferation inhibition and apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the bladder. J Surg Oncol 2013; 107: 201-205.
85. Bian XJ, Zhang GM, Gu CY, et al. Down-regulation of Dicer and Ago2 is associated with cell proliferation and apoptosis in prostate cancer. Tumour Biol 2014; 35: 11571-11578.
86. Zhang J, Zhang XH, Wang CX, et al. Dysregulation of microRNA biosynthesis enzyme Dicer plays an important role in gastric cancer progression. Int J Clin Exp Pathol 2014; 7: 1702-1707.
87. Gao C, Li X, Tong B, et al. Up-regulated expression of Dicer reveals poor prognosis in laryngeal squamous cell carcinoma. Acta Otolaryngol 2014; 134: 959-963.
88. Passon N, Gerometta A, Puppin C, et al. Expression of Dicer and Drosha in triple-negative breast cancer. J Clin Pathol 2012; 65: 320-326.
89. Pickering BF, Yu D, Van Dyke MW. Nucleolin protein interacts with microprocessor complex to affect biogenesis of microRNAs 15a and 16. J Biol Chem 2011; 286: 44095-44103.
90. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008; 454: 56-61.
91. Pichiorri F, Palmieri D, De Luca L, et al. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med 2013; 210: 951-968.
92. Tsang J, Zhu J, van Oudenaarden A. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell 2007; 26: 753-767.
93. Yu X, Lin J, Zack DJ, et al. Analysis of regulatory network topology reveals functionally distinct classes of microRNAs. Nucleic Acids Res 2008; 36: 6494-6503.
94. Fazi F, Rosa A, Fatica A, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005; 123: 819-831.
95. Davis BN, Hilyard AC, Nguyen PH, et al. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol Cell 2010; 39: 373-384.
96. Suzuki HI, Yamagata K, Sugimoto K, et al. Modulation of microRNA processing by p53. Nature 2009; 460: 529-533.
97. Zhang X, Wan G, Berger FG, et al. The ATM kinase induces microRNA biogenesis in the DNA damage response. Mol Cell 2011; 41: 371-383.
98. Li Y, Choi PS, Casey SC, et al. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell 2014; 26: 262-272.
99. Kawai S, Amano A. BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex. J Cell Biol 2012; 197: 201-208.
100. Shen J, Xia W, Khotskaya YB, et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 2013; 497: 383-387.
101. Guo QJ, Mills JN, Bandurraga SG, et al. MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer. Breast Cancer Res 2013; 15: R70.
102. Jurmeister S, Baumann M, Balwierz A, et al. MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol 2012; 32: 633-651.
103. Yao Y, Hu J, Shen Z, et al. MiR-200b expression in breast cancer: a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1. J Cell Mol Med 2015.
104. Li C, Nguyen HT, Zhuang Y, et al. Comparative profiling of miRNA expression of lung adenocarcinoma cells in two-dimensional and three-dimensional cultures. Gene 2012; 511: 143-150.
105. Nguyen HT, Li C, Lin Z, et al. The microRNA expression associated with morphogenesis of breast cancer cells in three-dimensional organotypic culture. Oncol Rep 2012; 28: 117-126.
106. Pramanik D, Campbell NR, Karikari C, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 2011; 10: 1470-1480.
107. Ma Q, Jiang Q, Pu Q, et al. MicroRNA-143 inhibits migration and invasion of human non-small-cell lung cancer and its relative mechanism. Int J Biol Sci 2013; 9: 680-692.
108. Seviour EG, Sehgal V, Lu Y, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene 2015.
109. Bockhorn J, Prat A, Chang YF, et al. Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. Cancer Res 2014; 74: 7406-7417.
110. Yan LX, Wu QN, Zhang Y, et al. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res 2011; 13: R2.
111. Zhu M, Yi M, Kim CH, et al. Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage. Genome Biol 2011; 12: R77.
112. Trang P, Medina PP, Wiggins JF, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010; 29: 1580-1587.
113. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006; 103: 7024-7029.
114. Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010; 18: 282-293.
115. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405-414.
116. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17: 28-40.
117. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006; 103: 12481-12486.
118. Santanam U, Zanesi N, Efanov A, et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A 2010; 107: 12210-12215.
119. O'Flaherty JD, Barr M, Fennell D, et al. The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy. J Thorac Oncol 2012; 7: 1880-1890.
120. Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112: 4793-4807.
121. Shukla S, Meeran SM. Epigenetics of cancer stem cells: Pathways and therapeutics. Biochim Biophys Acta 2014; 1840: 3494-3502.
122. Si H, Sun X, Chen Y, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol 2013; 139: 223-229.
123. Chhabra R, Saini N. MicroRNAs in cancer stem cells: current status and future directions. Tumour Biol 2014; 35: 8395-8405.
124. Cai WY, Wei TZ, Luo QC, et al. The Wnt-beta-catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion. J Cell Sci 2013; 126: 2877-2889.
125. Jakopovic M, Thomas A, Balasubramaniam S, et al. Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. Front Oncol 2013; 3: 261.
126. Rutnam ZJ, Yang BB. The involvement of microRNAs in malignant transformation. Histol Histopathol 2012; 27: 1263-1270.
127. Liu C, Kelnar K, Vlassov AV, et al. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res 2012; 72: 3393-3404.
128. Bao B, Ali S, Ahmad A, et al. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Stem Cells Dev 2014; 23: 1947-1958.
129. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006; 124: 1111-1115.
130. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131: 1109-1123.
131. Bu P, Chen KY, Chen JH, et al. A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell 2013; 12: 602-615.
132. Hwang WL, Jiang JK, Yang SH, et al. MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. Nat Cell Biol 2014; 16: 268-280.
133. Han M, Liu M, Wang Y, et al. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 2012; 7: e39520.
134. Yang S, Li Y, Gao J, et al. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene 2013; 32: 4294-4303.
135. Hatfield S, Ruohola-Baker H. microRNA and stem cell function. Cell Tissue Res 2008; 331: 57-66.
136. Iliopoulos D, Lindahl-Allen M, Polytarchou C, et al. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 2010; 39: 761-772.
137. Polytarchou C, Iliopoulos D, Struhl K. An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci U S A 2012; 109: 14470-14475.
138. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487-1495.
139. Sun X, Jiao X, Pestell TG, et al. MicroRNAs and cancer stem cells: the sword and the shield. Oncogene 2014; 33: 4967-4977.
140. Han M, Liu M, Wang Y, et al. Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol Cell Biochem 2012; 363: 427-436.
141. Zhang ZJ, Ma SL. miRNAs in breast cancer tumorigenesis (Review). Oncol Rep 2012; 27: 903-910.
142. Schwarzenbacher D, Balic M, Pichler M. The role of microRNAs in breast cancer stem cells. Int J Mol Sci 2013; 14: 14712-14723.
143. Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011; 121: 3786-3788.
144. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
145. Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 2001; 6: 375-392.
146. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-991.
147. Carlson RW, Allred DC, Anderson BO, et al. Invasive breast cancer. J Natl Compr Canc Netw 2011; 9: 136-222.
148. Opstal-van Winden AW, Rodenburg W, Pennings JL, et al. A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int J Mol Sci 2012; 13: 13587-13604.
149. Sinn P, Aulmann S, Wirtz R, et al. Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility. Geburtshilfe Frauenheilkd 2013; 73: 932-940.
150. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012; 6: 590-610.
151. Mar-Aguilar F, Rodriguez-Padilla C, Resendez-Perez D. Use of serum-circulating miRNA profiling for the identification of breast cancer biomarkers. Methods Mol Biol 2014; 1165: 71-80.
152. Chan M, Liaw CS, Ji SM, et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 2013; 19: 4477-4487.
153. Nassar FJ, El Sabban M, Zgheib NK, et al. miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study. PLoS One 2014; 9: e107566.
154. Zhang W, Liu J, Wang G. The role of microRNAs in human breast cancer progression. Tumour Biol 2014; 35: 6235-6244.
155. Corcoran C, Friel AM, Duffy MJ, et al. Intracellular and extracellular microRNAs in breast cancer. Clin Chem 2011; 57: 18-32.
156. Ozgun A, Karagoz B, Bilgi O, et al. MicroRNA-21 as an indicator of aggressive phenotype in breast cancer. Onkologie 2013; 36: 115-118.
157. Dong G, Liang X, Wang D, et al. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol 2014; 31: 57.
158. Anastasov N, Hofig I, Vasconcellos IG, et al. Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells. Radiat Oncol 2012; 7: 206.
159. Min W, Wang B, Li J, et al. The expression and significance of five types of miRNAs in breast cancer. Med Sci Monit Basic Res 2014; 20: 97-104.
160. Li J, Zhang Y, Zhang W, et al. Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation. Int J Surg Oncol 2013; 2013: 875078.
161. Piva R, Spandidos DA, Gambari R. From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). Int J Oncol 2013; 43: 985-994.
162. Christodoulatos GS, Dalamaga M. Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis? World J Clin Oncol 2014; 5: 71-81.
163. Tang J, Ahmad A, Sarkar FH. The role of microRNAs in breast cancer migration, invasion and metastasis. Int J Mol Sci 2012; 13: 13414-13437.
164. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070.
165. Sandhu R, Rein J, D'Arcy M, et al. Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status. Carcinogenesis 2014; 35: 2567-2575.
166. Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol 2013; 15: 546-554.
167. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-688.
168. Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, et al. The locus of microRNA-10b: a critical target for breast cancer insurgence and dissemination. Cell Cycle 2013; 12: 2371-2375.
169. Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, et al. miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med 2012; 4: 1214-1229.
170. Hu J, Xu J, Wu Y, et al. Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. Tumour Biol 2015; 36: 251-258.
171. Zhao FL, Dou YC, Wang XF, et al. Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer. Mol Biol Rep 2014; 41: 5913-5922.
172. Kim SJ, Shin JY, Lee KD, et al. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res 2012; 14: R14.
173. Shukla K, Sharma AK, Ward A, et al. MicroRNA-30c-2-3p negatively regulates NF-kappaB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. Mol Oncol 2015.
174. Jang K, Ahn H, Sim J, et al. Loss of microRNA-200a expression correlates with tumor progression in breast cancer. Transl Res 2014; 163: 242-251.
175. Yan Y, Zhang F, Fan Q, et al. Breast cancer-specific TRAIL expression mediated by miRNA response elements of let-7 and miR-122. Neoplasma 2014; 61: 672-679.
176. Xie R, Wang Y, Nie W, et al. Lin28B expression correlates with aggressive clinicopathological characteristics in breast invasive ductal carcinoma. Cancer Biother Radiopharm 2014; 29: 215-220.
177. Bussing I, Slack FJ, Grosshans H. let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 2008; 14: 400-409.
178. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol 2008; 18: 505-516.
179. Su JL, Chen PS, Johansson G, Kuo ML. Function and regulation of let-7 family microRNAs. Microrna 2012; 1: 34-39.
180. Yun J, Frankenberger CA, Kuo WL, et al. Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J 2011; 30: 4500-4514.
181. Worringer KA, Rand TA, Hayashi Y, et al. The let-7/LIN-41 pathway regulates reprogramming to human induced pluripotent stem cells by controlling expression of prodifferentiation genes. Cell Stem Cell 2014; 14: 40-52.
182. Jiang R, Li Y, Zhang A, et al. The acquisition of cancer stem cell-like properties and neoplastic transformation of human keratinocytes induced by arsenite involves epigenetic silencing of let-7c via Ras/NF-kappaB. Toxicol Lett 2014; 227: 91-98.
183. Mattie MD, Benz CC, Bowers J, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006; 5: 24.
184. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103: 2257-2261.
185. Gowrishankar B, Ibragimova I, Zhou Y, et al. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 2014; 15: 329-341.
186. Tang Z, Ow GS, Thiery JP, et al. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. Int J Cancer 2014; 134: 306-318.
187. Li H, Bian C, Liao L, et al. miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat 2011; 126: 565-575.
188. Leung CM, Chen TW, Li SC, et al. MicroRNA expression profiles in human breast cancer cells after multifraction and single-dose radiation treatment. Oncol Rep 2014; 31: 2147-2156.
189. Perez-Madrigal D, Finegan KG, Paramo B, Tournier C. The extracellular-regulated protein kinase 5 (ERK5) promotes cell proliferation through the down-regulation of inhibitors of cyclin dependent protein kinases (CDKs). Cell Signal 2012; 24: 2360-2368.
190. Zhang G, Zhou H, Xiao H, et al. MicroRNA-92a functions as an oncogene in colorectal cancer by targeting PTEN. Dig Dis Sci 2014; 59: 98-107.
191. Li L, Shi JY, Zhu GQ, Shi B. MiR-17-92 cluster regulates cell proliferation and collagen synthesis by targeting TGFB pathway in mouse palatal mesenchymal cells. J Cell Biochem 2012; 113: 1235-1244.
192. Kondo N, Toyama T, Sugiura H, et al. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 2008; 68: 5004-5008.
193. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007; 21: 1132-1147.
194. Liu H, Cao YD, Ye WX, Sun YY. Effect of microRNA-206 on cytoskeleton remodelling by downregulating Cdc42 in MDA-MB-231 cells. Tumori 2010; 96: 751-755.
195. Li Y, Hong F, Yu Z. Decreased expression of microRNA-206 in breast cancer and its association with disease characteristics and patient survival. J Int Med Res 2013; 41: 596-602.
196. Elliman SJ, Howley BV, Mehta DS, et al. Selective repression of the oncogene cyclin D1 by the tumor suppressor miR-206 in cancers. Oncogenesis 2014; 3: e113.
197. Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603.
198. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-256.
199. Sochor M, Basova P, Pesta M, et al. Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer 2014; 14: 448.
200. Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev 2012; 21: 1236-1243.
201. Gong J, Luk F, Jaiswal R, Bebawy M. Microparticles Mediate the Intercellular Regulation of microRNA-503 and Proline-Rich Tyrosine Kinase 2 to Alter the Migration and Invasion Capacity of Breast Cancer Cells. Front Oncol 2014; 4: 220.
202. Blenkiron C, Goldstein LD, Thorne NP, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007; 8: R214.
203. Lowery AJ, Miller N, Devaney A, et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009; 11: R27.
204. Foekens JA, Sieuwerts AM, Smid M, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 2008; 105: 13021-13026.
205. Gasparini P, Cascione L, Fassan M, et al. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 2014; 5: 1174-1184.
206. Rothe F, Ignatiadis M, Chaboteaux C, et al. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 2011; 6: e20980.
207. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-1741.
208. Roth C, Rack B, Muller V, et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010; 12: R90.
209. Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010; 251: 499-505.
210. Wu Q, Lu Z, Li H, et al. Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnol 2011; 2011: 597145.
211. Hu Z, Dong J, Wang LE, et al. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 2012; 33: 828-834.
212. Lyng MB, Laenkholm AV, Sokilde R, et al. Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study. PLoS One 2012; 7: e36170.
213. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, et al. MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 2011; 127: 43-51.
214. Maillot G, Lacroix-Triki M, Pierredon S, et al. Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res 2009; 69: 8332-8340.
215. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012; 9: e1001216.
216. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18: 977-984.
217. Ichikawa T, Sato F, Terasawa K, et al. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS One 2012; 7: e31422.
218. Fassan M, Pizzi M, Realdon S, et al. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. Hum Pathol 2013; 44: 1804-1810.
219. Scott GK, Goga A, Bhaumik D, et al. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479-1486.
220. Dangi-Garimella S, Yun J, Eves EM, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J 2009; 28: 347-358.
221. Le XF, Almeida MI, Mao W, et al. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer. PLoS One 2012; 7: e41170.
222. Jung EJ, Santarpia L, Kim J, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012; 118: 2603-2614.
223. Sun Y, Wang M, Lin G, et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One 2012; 7: e47003.
224. Joosse SA, Muller V, Steinbach B, et al. Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases. Br J Cancer 2014; 111: 909-917.
225. Kleivi Sahlberg K, Bottai G, Naume B, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res 2015; 21: 1207-1214.
226. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
227. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther 2011; 18: 1121-1126.
228. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther 2006; 13: 496-502.
229. Orom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006; 372: 137-141.
230. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-689.
231. Saito Y, Hashimoto Y, Arai M, et al. Chemistry, properties, and in vitro and in vivo applications of 2'-O-methoxyethyl-4'-thioRNA, a novel hybrid type of chemically modified RNA. Chembiochem 2014; 15: 2535-2540.
232. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4: 721-726.
233. Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA 2010; 16: 2043-2050.
234. Yang X, Cheng Y, Li P, et al. A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis. Tumour Biol 2015; 36: 383-391.
235. Huang S, Chen Y, Wu W, et al. miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS One 2013; 8: e80707.
236. Akao Y, Nakagawa Y, Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 2006; 16: 845-850.
237. Rosi NL, Giljohann DA, Thaxton CS, et al. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006; 312: 1027-1030.
238. Elbakry A, Zaky A, Liebl R, et al. Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett 2009; 9: 2059-2064.
239. Lee JS, Green JJ, Love KT, et al. Gold, poly(beta-amino ester) nanoparticles for small interfering RNA delivery. Nano Lett 2009; 9: 2402-2406.
240. Ekin A, Karatas OF, Culha M, Ozen M. Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells. J Gene Med 2014; 16: 331-335.
241. Yang G, Wu D, Zhu J, et al. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. Oncol Rep 2013; 30: 877-889.
242. Gong C, Yao Y, Wang Y, et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2011; 286: 19127-19137.
243. Allen KE, Weiss GJ. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther 2010; 9: 3126-3136.
244. Bai H, Xu R, Cao Z, et al. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 2011; 585: 402-408.
245. Park EY, Chang E, Lee EJ, et al. Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res 2014; 74: 7573-7582.
246. Yin J, Zheng G, Jia X, et al. A Bmi1-miRNAs cross-talk modulates chemotherapy response to 5-fluorouracil in breast cancer cells. PLoS One 2013; 8: e73268.
247. Xin H, Li X, Yang B, et al. Blood-based multiple-microRNA assay displays a better diagnostic performance than single-microRNA assay in the diagnosis of breast tumor. Tumour Biol 2014; 35: 12635-12643.